erbb3 speci c Search Results


93
Santa Cruz Biotechnology erbb3 speci c
Figure 3 Tyrosine phosphorylation of <t>ErbB3</t> in response to NDF and BTC but not EGF. SKBR3 cells were treated with 1 nM of the indicated ligands for 10 min and lysed. ErbB3 was immunoprecipitated from 1 mg total lysate using C17 antiserum, subjected to SDS ± PAGE, blotted and probed with an anti- phosphotyrosine mAb. The membrane was then stripped and reprobed with ErbB3 speci®c C17 serum
Erbb3 Speci C, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/erbb3+speci+c/ErbB-3+Antibody/pm10376522-257-12-19
Average 93 stars, based on 1 article reviews
erbb3 speci c - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier

Image Search Results


Figure 3 Tyrosine phosphorylation of ErbB3 in response to NDF and BTC but not EGF. SKBR3 cells were treated with 1 nM of the indicated ligands for 10 min and lysed. ErbB3 was immunoprecipitated from 1 mg total lysate using C17 antiserum, subjected to SDS ± PAGE, blotted and probed with an anti- phosphotyrosine mAb. The membrane was then stripped and reprobed with ErbB3 speci®c C17 serum

Journal: Oncogene

Article Title: NDF/heregulin-induced cell cycle changes and apoptosis in breast tumour cells: role of PI3 kinase and p38 MAP kinase pathways.

doi: 10.1038/sj.onc.1202700

Figure Lengend Snippet: Figure 3 Tyrosine phosphorylation of ErbB3 in response to NDF and BTC but not EGF. SKBR3 cells were treated with 1 nM of the indicated ligands for 10 min and lysed. ErbB3 was immunoprecipitated from 1 mg total lysate using C17 antiserum, subjected to SDS ± PAGE, blotted and probed with an anti- phosphotyrosine mAb. The membrane was then stripped and reprobed with ErbB3 speci®c C17 serum

Article Snippet: Antibodies used were: ErbB2 speci®c 21N polyclonal antiserum (Hynes et al., 1989), ErbB3 speci®c a nity-puri®ed polyclonal antiserum C17 (Santa Cruz Biotechnology), phosphotyrosine-speci®c mAb, p85-speci®c antiserum (UBI), c-Src speci®c Ab-1 mAb (Calbiochem), anti-phospho-speci®c p38a and p38b/b2 MAPK (Thr180/ Tyr182) polyclonal antiserum, anti-phospho-speci®c p44/42 ERK (Thr202/Tyr204) polyclonal antiserum, anti-phosphospeci®c Akt/PKB (Ser473) polyclonal antiserum, antiphospho-speci®c Cdc2 (Cdk1) (Tyr15) polyclonal antiserum (New England Biolabs MA, USA), anti-Cdc2 polyclonal antiserum (Gibco), anti-cyclin A polyclonal antiserum (Lisztwan et al., 1998, supplied by W Krek, FMI), and anti cyclin B1 polyclonal antiserum, H-433 (Santa Cruz).

Techniques: Phospho-proteomics, Immunoprecipitation, SDS Page, Membrane

Figure 5 Comparison of signal transduction by NDF and BTC. SKBR3 cells were treated with 1 nM of NDF or BTC for the indicated times or left untreated (con). (a, b) 70 mg total lysate was subjected to SDS ± PAGE, blotted and probed with antisera speci®c for the active forms of ERK 1 and 2 (a). The blot was stripped and then probed for the active forms p38 MAPK (b). (c) ErbB3 was immunoprecipitated from 1 mg total lysate, subjected to SDS ± PAGE, blotted and probed with antiserum speci®c for the p85 subunit of PI3K. (d) 50 mg total lysate was subjected to SDS ± PAGE, blotted and probed with antisera speci®c for the active form of PKB

Journal: Oncogene

Article Title: NDF/heregulin-induced cell cycle changes and apoptosis in breast tumour cells: role of PI3 kinase and p38 MAP kinase pathways.

doi: 10.1038/sj.onc.1202700

Figure Lengend Snippet: Figure 5 Comparison of signal transduction by NDF and BTC. SKBR3 cells were treated with 1 nM of NDF or BTC for the indicated times or left untreated (con). (a, b) 70 mg total lysate was subjected to SDS ± PAGE, blotted and probed with antisera speci®c for the active forms of ERK 1 and 2 (a). The blot was stripped and then probed for the active forms p38 MAPK (b). (c) ErbB3 was immunoprecipitated from 1 mg total lysate, subjected to SDS ± PAGE, blotted and probed with antiserum speci®c for the p85 subunit of PI3K. (d) 50 mg total lysate was subjected to SDS ± PAGE, blotted and probed with antisera speci®c for the active form of PKB

Article Snippet: Antibodies used were: ErbB2 speci®c 21N polyclonal antiserum (Hynes et al., 1989), ErbB3 speci®c a nity-puri®ed polyclonal antiserum C17 (Santa Cruz Biotechnology), phosphotyrosine-speci®c mAb, p85-speci®c antiserum (UBI), c-Src speci®c Ab-1 mAb (Calbiochem), anti-phospho-speci®c p38a and p38b/b2 MAPK (Thr180/ Tyr182) polyclonal antiserum, anti-phospho-speci®c p44/42 ERK (Thr202/Tyr204) polyclonal antiserum, anti-phosphospeci®c Akt/PKB (Ser473) polyclonal antiserum, antiphospho-speci®c Cdc2 (Cdk1) (Tyr15) polyclonal antiserum (New England Biolabs MA, USA), anti-Cdc2 polyclonal antiserum (Gibco), anti-cyclin A polyclonal antiserum (Lisztwan et al., 1998, supplied by W Krek, FMI), and anti cyclin B1 polyclonal antiserum, H-433 (Santa Cruz).

Techniques: Comparison, Transduction, SDS Page, Immunoprecipitation